Should I buy or sell Adverum Biotechnologies stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADVM shares. View ADVM analyst ratings or view top-rated stocks .

What is Adverum Biotechnologies' stock price target for 2024?

3 brokers have issued twelve-month price targets for Adverum Biotechnologies' shares. Their ADVM share price targets range from $4.00 to $60.00. On average, they predict the company's share price to reach $34.67 in the next year. This suggests a possible upside of 210.9% from the stock's current price. View analysts price targets for ADVM or view top-rated stocks among Wall Street analysts .

How have ADVM shares performed in 2024?

Adverum Biotechnologies' stock was trading at $7.5280 on January 1st, 2024. Since then, ADVM shares have increased by 48.1% and is now trading at $11.15. View the best growth stocks for 2024 here .

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 890,000 shares, an increase of 37.2% from the March 15th total of 648,500 shares. Based on an average daily volume of 258,600 shares, the days-to-cover ratio is presently 3.4 days. Currently, 6.0% of the shares of the stock are short sold. View Adverum Biotechnologies' Short Interest .

When is Adverum Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ADVM earnings forecast .

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) posted its earnings results on Monday, March, 18th. The biotechnology company reported ($2.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.80) by $0.50.

When did Adverum Biotechnologies' stock split?

Shares of Adverum Biotechnologies reverse split on the morning of Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com . Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC) , California Resources (CRC) , Xtrackers California Municipal Bond ETF (CA) , BlackRock (BLK) , Amarin (AMRN) , Endologix (ELGX) , Immunomedics (IMMU) , Advanced Micro Devices (AMD) , Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA) .

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free ADVM Stock Alerts

$11.15

-0.20 (-1.76%)

(As of 04/18/2024 ET)

Compare

Today's Range: $11.01
▼
$11.58
50-Day Range: $11.35
▼
$22.90
52-Week Range: $7.10
▼
$29.70

Volume: 103,592 shs
Average Volume: 241,246 shs
Market Capitalization: $231.36 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.67

Get Adverum Biotechnologies alerts:

Adverum Biotechnologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 210.9% Upside
$34.67 Price Target
Short Interest: Bearish
5.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: 0.85
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$135,000 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($5.18) to ($5.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.00 out of 5 stars

Medical Sector

170th out of 918 stocks

Biological Products, Except Diagnostic Industry

17th out of 147 stocks

3.5

Analyst's Opinion

Consensus Rating
Adverum Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Adverum Biotechnologies has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.95% of the float of Adverum Biotechnologies has been sold short.
Short Interest Ratio / Days to Cover
Adverum Biotechnologies has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adverum Biotechnologies has recently increased by 37.24%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adverum Biotechnologies does not currently pay a dividend.
Dividend Growth
Adverum Biotechnologies does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Adverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Adverum Biotechnologies is -0.78.

3.2

News and Social Media Coverage

News Sentiment
Adverum Biotechnologies has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Adverum Biotechnologies this week, compared to 1 article on an average week.
Search Interest
6 people have searched for ADVM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adverum Biotechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Adverum Biotechnologies is held by insiders.
Percentage Held by Institutions
48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($5.18) to ($5.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adverum Biotechnologies is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adverum Biotechnologies is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adverum Biotechnologies has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Adverum Biotechnologies Stock (NASDAQ:ADVM)

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

ADVM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADVM Stock News Headlines

April 18, 2024 | money.usnews.com

Adverum Biotechnologies Inc

April 12, 2024 | americanbankingnews.com

Adverum Biotechnologies (NASDAQ:ADVM) Shares Cross Below Two Hundred Day Moving Average of $12.25

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 12, 2024 | americanbankingnews.com

Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Expands By 37.2%

March 28, 2024 | markets.businessinsider.com

Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)

March 21, 2024 | markets.businessinsider.com

Positive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial Position

March 20, 2024 | finance.yahoo.com

Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments

March 19, 2024 | finance.yahoo.com

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

April 18, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

March 19, 2024 | markets.businessinsider.com

Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen

March 18, 2024 | investorplace.com

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023

March 18, 2024 | globenewswire.com

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

March 17, 2024 | seekingalpha.com

ADVM Adverum Biotechnologies, Inc.

March 6, 2024 | finance.yahoo.com

ADVM Apr 2024 5.000 call

March 6, 2024 | investorplace.com

Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop

February 28, 2024 | globenewswire.com

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

February 27, 2024 | investorplace.com

Stocks on the Launchpad: The Next 3 Market Sensations

February 25, 2024 | msn.com

Adverum Biotechnologies (ADVM) Price Target Increased by 10.53% to 4.28

February 22, 2024 | benzinga.com

Adverum Biotechnologies Stock (NASDAQ:ADVM), Short Interest Report

February 22, 2024 | investorplace.com

Unleash Massive Returns With These 3 Top Penny Stocks

February 15, 2024 | finance.yahoo.com

ADVM Feb 2024 4.000 call

February 13, 2024 | finance.yahoo.com

ADVM Sep 2024 2.500 put

February 12, 2024 | finance.yahoo.com

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 9, 2024 | uk.investing.com

Adverum Biotechnologies Inc (ADVM)

February 8, 2024 | msn.com

Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?

February 8, 2024 | finance.yahoo.com

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

February 7, 2024 | msn.com

Adverum Biotechnologies Awaits Court Decision on Settlement

See More Headlines

Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ADVM
CUSIP: N/A
CIK: 1501756
Web: www.adverum.com
Phone: (650) 656-9323
Fax: 650-329-8151
Employees: 121
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.67
High Stock Price Target: $60.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +210.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-117,170,000.00
Net Margins: N/A
Pretax Margin: -3,284.53%
Return on Equity: -98.65%
Return on Assets: -52.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.13
Quick Ratio: 4.13

Sales & Book Value

Annual Sales: $3.60 million
Price / Sales: 64.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.26 per share
Price / Book: 1.35

Miscellaneous

Outstanding Shares: 20,750,000
Free Float: 19,655,000
Market Cap: $231.36 million
Optionable: Optionable
Beta: 0.84

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Laurent Fischer (Age 60)
President, CEO & Director
Comp: $1.02M
Ms. Linda M. Rubinstein M.A. (Age 57)
CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $940.99k
Mr. Kishor Peter Soparkar J.D. (Age 52)
Chief Operating Officer
Comp: $674.98k
Dr. Setareh Seyedkazemi Pharm.D. (Age 49)
Chief Development Officer
Comp: $656.84k
Dr. R. Andrew Ramelmeier Ph.D. (Age 62)
Chief Technology Officer
Dr. Romuald Corbau Ph.D. (Age 55)
Chief Scientific Officer
Mr. John W. Rakow J.D. (Age 67)
Senior VP & General Counsel
Comp: $954.24k
Ms. Dena House
Chief People Officer
Ms. Carla Fiankan
Senior Vice President of Regulatory Affairs
Mr. Michael Steel
Senior Vice President of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADVM Stock Analysis - Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADVM shares.
View ADVM analyst ratings or view top-rated stocks.
What is Adverum Biotechnologies' stock price target for 2024?: 3 brokers have issued twelve-month price targets for Adverum Biotechnologies' shares. Their ADVM share price targets range from $4.00 to $60.00. On average, they predict the company's share price to reach $34.67 in the next year. This suggests a possible upside of 210.9% from the stock's current price.
View analysts price targets for ADVM or view top-rated stocks among Wall Street analysts.
How have ADVM shares performed in 2024?: Adverum Biotechnologies' stock was trading at $7.5280 on January 1st, 2024. Since then, ADVM shares have increased by 48.1% and is now trading at $11.15.
View the best growth stocks for 2024 here.
Are investors shorting Adverum Biotechnologies?: Adverum Biotechnologies saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 890,000 shares, an increase of 37.2% from the March 15th total of 648,500 shares. Based on an average daily volume of 258,600 shares, the days-to-cover ratio is presently 3.4 days. Currently, 6.0% of the shares of the stock are short sold.
View Adverum Biotechnologies' Short Interest.
When is Adverum Biotechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ADVM earnings forecast.
How were Adverum Biotechnologies' earnings last quarter?: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) posted its earnings results on Monday, March, 18th. The biotechnology company reported ($2.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.80) by $0.50.

When did Adverum Biotechnologies' stock split?: Shares of Adverum Biotechnologies reverse split on the morning of Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?: 3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.
What other stocks do shareholders of Adverum Biotechnologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).
How do I buy shares of Adverum Biotechnologies?: Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADVM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial